Literature DB >> 22240441

Novel antimicrobial-resistant bacteria among patients requiring chronic hemodialysis.

Graham M Snyder1, Erika M C D'Agata.   

Abstract

PURPOSE OF REVIEW: Antimicrobial-resistant bacteria (ARB) including resistant strains of Staphylococcus aureus, enterococci, and Gram-negative bacteria have the potential to cause serious infections among patients requiring chronic hemodialysis (CHD). The purpose of this article is to review novel ARB, which have emerged in this patient population, their mechanisms of transmission, and preventive efforts aimed at limiting their dissemination. RECENT
FINDINGS: New strains of ARB, including community-acquired methicillin-resistant S. aureus, S. aureus strains with reduced susceptibility to vancomycin, vancomycin-resistant S. aureus and multidrug-resistant Gram-negative bacteria (MDRGN), are emerging among the CHD population. Extended-spectrum β-lactamase Gram-negative bacteria (ESBLGN) are among the most common MDRGN strains. These ESBLGN are resistant to the great majority of antimicrobials. The carbapenems remain the only optimal antimicrobial choice to treat ESBLGN infections. Intrafacility spread of ARB in dialysis units occurs between patients through contaminated hands and clothes of healthcare workers (HCWs), as well as contaminated inanimate surfaces. Spread of ARB to family members of both patients and HCWs has also been documented.
SUMMARY: Colonization and infection with ARB continues to present a significant threat to patients receiving CHD. Interventions to reduce the spread of ARB should include infection control measures and judicious use of antimicrobials.

Entities:  

Mesh:

Year:  2012        PMID: 22240441     DOI: 10.1097/MNH.0b013e328350089b

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  9 in total

Review 1.  Medical safety in the care of the person with end-stage kidney disease.

Authors:  John V Duronville; Clarissa J Diamantidis
Journal:  Semin Dial       Date:  2018-01-07       Impact factor: 3.455

2.  Reevaluation of ceftazidime dosing recommendations in patients on continuous ambulatory peritoneal dialysis.

Authors:  Katie E Cardone; Darren W Grabe; Evan J Zasowski; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

3.  Clinical and Economic Benefits of Antimicrobial Stewardship Programs in Hemodialysis Facilities: A Decision Analytic Model.

Authors:  Erika M C D'Agata; Diana Tran; Josef Bautista; Douglas Shemin; Daniel Grima
Journal:  Clin J Am Soc Nephrol       Date:  2018-08-23       Impact factor: 8.237

4.  Patterns of Antimicrobial Use in an Outpatient Hemodialysis Unit.

Authors:  Sylvia Sivarajahkumar; Miranda So; Andrew M Morris; Charmaine Lok; Chaim M Bell; Marisa Battistella
Journal:  Can J Hosp Pharm       Date:  2022

5.  Factors associated with the receipt of antimicrobials among chronic hemodialysis patients.

Authors:  Graham M Snyder; Priti R Patel; Alexander J Kallen; James A Strom; J Kevin Tucker; Erika M C D'Agata
Journal:  Am J Infect Control       Date:  2016-05-13       Impact factor: 2.918

6.  Streptococcus acidominimus causing invasive disease in humans: a case series.

Authors:  Chaoneng Wu; Buqing Liang; Yunguo Gong; Lan Zhang; Yunzeng Zou; Junbo Ge
Journal:  J Med Case Rep       Date:  2014-02-17

7.  Evaluating Infection Prevention Strategies in Out-Patient Dialysis Units Using Agent-Based Modeling.

Authors:  Joanna R Wares; Barry Lawson; Douglas Shemin; Erika M C D'Agata
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

8.  COVID-19 modeling and non-pharmaceutical interventions in an outpatient dialysis unit.

Authors:  Hankyu Jang; Philip M Polgreen; Alberto M Segre; Sriram V Pemmaraju
Journal:  PLoS Comput Biol       Date:  2021-07-08       Impact factor: 4.475

9.  Post-antibiotic era in hemodialysis? Two case reports of simultaneous colonization and bacteremia by multidrug-resistant bacteria.

Authors:  Johanna M Vanegas; Lorena Salazar-Ospina; Gustavo A Roncancio; Julián Builes; Judy Natalia Jiménez
Journal:  J Bras Nefrol       Date:  2021 Oct-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.